ARVN Arvinas, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ARVN matters now
Arvinas, Inc. (ARVN) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.27 with -3.16% on the session and $533.6M in market capitalization; recent performance reads 1-month -10.29% and YTD -35.33%.
The latest financial table shown here is Q1 2026, with revenue of $15.6M, net income of $-57.6M, and EPS of $-0.90. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -51.9%.
The latest indexable market news headline is "Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data" from MarketBeat.
Additional event context on this page matters because analyst consensus is Hold with a median target of $14.50; recent insider activity includes Cacace Angela M filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.27
P/S
5.54
EV/EBITDA
-1.92
DCF Value
$-122.08
FCF Yield
-51.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.4%
Operating Margin
-279.3%
Net Margin
-247.5%
ROE
-44.4%
ROA
-34.2%
ROIC
-46.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.6M | $-57.6M | $-0.90 |
| Q4 2025 | $9.5M | $-67.4M | $-1.04 |
| FY 2025 | $262.6M | $-80.8M | $-1.28 |
| Q3 2025 | $41.9M | $-35.1M | $-0.48 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$14.75
Target (Median)
$14.50
Target Range
$10.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.75
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.